Revvity, Inc. · NYSE:RVTY
Revvity — PerkinElmer — J.P. Morgan Healthcare Conference 2022
35 slides from Revvity's conference presentation, Jan 11, 2022
Slide 1: J.P. Morgan Healthcare Conference
J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer January 11, 2022 1
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to ou
Slide 3: Who We Are: Innovating for a Healthier World
WHO WE ARE OUR MISSION Passionate about saving and Diagnostics transforming patients’ lives INNOVATING Focused on accelerating pre-clinical Life Sciences discoveries and enabling customers to for a deliver safe and effective therapies healthier Dedicated to ensuring the highest quality Food product
Slide 4: PerkinElmer Today
PERKINELMER TODAY Portfolio Mix* Diagnostics Consumables, ~25% Services, (Dx) ~45% Software Americas Asia ~80% ~30% $5.0B 2021e Europe Instruments revenue ~20% Discovery & Analytical 2021 Performance†: Continued to Deliver Record Results Solutions (DAS) Non-COVID COVID Adj. EPS Organic Growth Revenu
Slide 5: What You'll Hear Today
WHAT YOU’LL HEAR TODAY THE NEW PERKINELMER Transformation Enabling Faster Growth and Greater Value Creation 1. ATTRACTIVE & EXPANDED PORTFOLIO Providing complete solutions across Dx and LS 2. FOCUSED INTERNAL EXECUTION Clear progress across four strategic priorities 3. STRONG FINANCIAL OUTLOOK Deliv
Slide 6: What You'll Hear Today
WHAT YOU’LL HEAR TODAY THE NEW PERKINELMER Transformation Enabling Faster Growth and Greater Value Creation 1. ATTRACTIVE & EXPANDED PORTFOLIO Providing complete solutions across Dx and LS 2. FOCUSED INTERNAL EXECUTION Clear progress across four strategic priorities 3. STRONG FINANCIAL OUTLOOK Deliv
Slide 7: Attractive & Expanded Portfolio
ATTRACTIVE & EXPANDED PORTFOLIO TODAY'S DISCUSSION: THE BUILDING BLOCKS OF OUR SUCCESS PKI Revenue Pre-2018 DIAGNOSTICS LIFE SCIENCES Approaching $3B $2B+ DAS segment, with Strong Core 60% Capabilities global portfolio with LS representing ~65% of Dx & LS leading franchises ‘21 pro-forma revenue 202
Slide 8: Attractive & Expanded Portfolio
ATTRACTIVE & EXPANDED PORTFOLIO TODAY’S DISCUSSION: THE BUILDING BLOCKS OF OUR SUCCESS PKI Revenue Pre-2018 DIAGNOSTICS LIFE SCIENCES Approaching $3B $2B+ DAS segment, with Strong Core 60% Capabilities global portfolio with LS representing ~65% of Dx & LS leading franchises ‘21 pro-forma revenue 202
Slide 9: Diagnostics At A Glance
DIAGNOSTICS AT A GLANCE EXPANSION INTO AREAS OUTSIDE KEY POSITIONS Reproductive Applied REPRODUCTIVE HEALTH (RH) Health Genomics ~30% ~80% #1 OVERALL REPRODUCTIVE Reproductive $2.9B 2021e Sales outside Sales outside Health Solutions include newborn screening, NIPT, biochemical screening, and pre-ecl
Slide 10: Providing Seamless Diagnostics Workflows At Scale
PROVIDING SEAMLESS DIAGNOSTICS WORKFLOWS AT SCALE From Assays to Integrated Expansion into Adjacent Markets Comprehensive Portfolio Workflows Expanding our Total Driving best-in-class Augmenting our Addressable Market to detection detection through $35B with the extension capabilities across a end-t
Slide 11: Our 2021 Strategic M&A Extended Our Portfolio
OUR 2021 STRATEGIC M&A EXTENDED OUR PORTFOLIO INTO ATTRACTIVE & COMPLEMENTARY NEW MARKETS Expansion into Expanding our Total Addressable Market to $35B with the Adjacent Markets extension into new infectious disease and autoimmune markets TUBERCULOSIS ENDOCRINOLOGY Recognized global leader of Develo
Slide 12: Delivering Comprehensive Solutions For Any Lab's Needs
DELIVERING COMPREHENSIVE SOLUTIONS FOR ANY LAB’S NEEDS Comprehensive Driving best-in-class detection capabilities across a Portfolio full array of customers settings Testing Setting Highly automated, more centralized Community and near-patient settings explorerTM SuperFlexTM Workstation Accentis i10
Slide 13: Driving Unparalleled Detection Across The Workflow
DRIVING UNPARALLELED DETECTION ACROSS THE WORKFLOW From Assays to Augmenting our detection through Integrated Workflows end-to-end automation and integrated digital tools Example Offerings across Workflow End-to-end workflow in Applied Genomics … Sample DNA / RNA Sample Data QC Assays RESULT Homogen
Slide 14: In Action: Complementing Our Leading Latent TB Test
IN ACTION: COMPLEMENTING OUR LEADING LATENT TB TEST THROUGH VERTICAL WORKFLOW INTEGRATION EXPANDED TO LATENT TB TESTING: NOW BRINGING ADDITIONAL VALUE TO OUR CUSTOMERS Best-in-Class Assay THROUGH PKI’S COMPLETE WORKFLOW & SERVICES Example Performance Reagent Programs: Automation Programs: driving in
Slide 15: Diagnostics Summary: Leading Positions In Key Markets
DIAGNOSTICS SUMMARY: LEADING POSITIONS IN KEY MARKETS Expansion From Assays to Comprehensive into Adjacent Integrated Portfolio Markets Workflows Strong +HSD Growth Outlook Nearly >$2B deployed capital Tripled Core since 2015 Dx revenue since 2015 15
Slide 16: Attractive & Expanded Portfolio
ATTRACTIVE & EXPANDED PORTFOLIO TODAY’S DISCUSSION: THE BUILDING BLOCKS OF OUR SUCCESS PKI Revenue Pre-2018 DIAGNOSTICS LIFE SCIENCES Approaching $3B $2B+ DAS segment, with Strong Core 60% Capabilities global portfolio with LS representing ~65% of Dx & LS leading franchises ‘21 pro-forma revenue 202
Slide 17: Discovery & Analytical Solutions At A Glance
DISCOVERY & ANALYTICAL SOLUTIONS AT A GLANCE LS REVENUE IN DAS KEY POSITIONS Life Sciences <45% vs. ~65% #1 PRE-CLINICAL IMAGING in 2015 in 2021* Pre-Clinical Analysis Best-in-class overall pre-clinical Food $2.1B2021e ACCELERATED GROWTH workflow utilizing multi’omics revenue ~7-9% Discovery #2 FLOW
Slide 18: Addressing Our Customers' Most Acute Needs
COMPLEMENTING OUR CORE WITH UNIQUE CAPABILITIES ADDRESSING OUR CUSTOMERS’ MOST ACUTE NEEDS Best-in-Class Pre-Clinical Differentiating Cell and Discovery Scaling end-to-end Gene Therapy solutions which help close the chasm from Research to Clinic Leveraging our >$700M reagents attractive existing and
Slide 19: Scaling Our Strategic Focus Areas
SCALING OUR STRATEGIC FOCUS AREAS Best-in-Class Pre-Clinical Differentiating Cell and Gene Therapy Discovery Designs and engineers Develops optimized Global developer and Leading cell genetically modified viral vectors for Cell & manufacturer of high-quality counting and cell Overview cells for rese
Slide 20: Uniquely Positioned Across The Pharma Discovery Workflow
UNIQUELY POSITIONED ACROSS THE PHARMA DISCOVERY WORKFLOW Best-in-Class ✓ Speed to market Solutions for Pharma / Biotech at Pre-Clinical Increasing our ✓ Productivity every stage of the Discovery process Discovery customers’ ✓ Success rate Tools to Feed the Biomarker Lead Gen & Biomarker Pipeline Pre
Slide 21: A Compelling End-to-End Solution For Cell & Gene Therapy
A COMPELLING END-TO-END SOLUTION FOR CELL & GENE THERAPY CUSTOMERS Differentiating Offering a ✓ Tools for early-stage optimization of therapies Cell & Gene complete ✓ Enabling reduction of development timeline Therapy solution from Years to Months Differentiated Customer Offering: Rare Disease or On
Slide 22: Our Differentiated Life Sciences Expansion Further Bridges Into Diagnostics
OUR DIFFERENTIATED LIFE SCIENCES EXPANSION FURTHER BRIDGES INTO DIAGNOSTICS LIFE SCIENCES ✓ Pre-clinical Accelerates new product biomarkers development, enabling our ✓ Cell & Gene customers to deliver faster, Therapy workflows better therapies ✓ Antibodies DIAGNOSTICS ✓ Recombinant Proteins New Cont
Slide 23: DAS Summary: Capitalizing On Strong Life Sciences Portfolio
DAS SUMMARY: CAPITALIZING ON STRONG LIFE SCIENCES PORTFOLIO New Content Portfolio Expansion Building a Development Enables Best-In-Class Foundation in Drives Rapid Pre-Clinical Discovery Cell & Gene Therapy Innovation Driving shift from MSD to SUSTAINABLE HSD GROWTH LIFE SCIENCES REVENUE IN DAS ~$0.
Slide 24: What You'll Hear Today
WHAT YOU’LL HEAR TODAY THE NEW PERKINELMER Transformation Enabling Faster Growth and Greater Value Creation 1. ATTRACTIVE & EXPANDED PORTFOLIO Providing complete solutions across Dx and LS 2. FOCUSED INTERNAL EXECUTION Clear progress across four strategic priorities 3. STRONG FINANCIAL OUTLOOK Deliv
Slide 25: Focused Internal Execution Across Our Strategic Priorities
FOCUSED INTERNAL EXECUTION ACROSS OUR STRATEGIC PRIORITIES TECHNOLOGY & INNOVATION OPERATIONAL EXCELLENCE ✓ Cost-out ✓ Global Agility ✓ FCF Conversion ✓ Customer-Centric ✓ Total Quality ➢ Investing in New Frontiers: NPI ➢ Acquisition Integration: approach has launches up 15% in 2021 been vital to ea
Slide 26: Operational Excellence: Our Flexible Integration Playbooks Approach
OPERATIONAL EXCELLENCE: OUR FLEXIBLE INTEGRATION PLAYBOOKS APPROACH HAS BEEN VITAL TO OUR EARLY SUCCESSES No “One Size Fits All” CROSS- Formula COMPANY INNOVATION SUMMIT Putting PEOPLE Prioritized Employee Experience SCIENCE & CO-SELLING PEOPLE first & MARKETING GOVERNANCE PROGRAM Frequent Stakehold
Slide 27: Talent And Culture: Making Initial Progress On Key ESG Goals
TALENT AND CULTURE: MAKING INITIAL PROGRESS ON KEY ESG GOALS STATED GOAL PROGRESS 30% reduction of Scope 1 & 2 EMISSIONS Decreased 2020 Scope 1 and 2 Emissions by 2030 (vs. 2019) and REDUCTION Emissions by 8.5% net carbon neutrality by 2040 Achieve 15% reduction in non- 5 tons of lab equipment, 122
Slide 28: What You'll Hear Today
WHAT YOU’LL HEAR TODAY THE NEW PERKINELMER Transformation Enabling Faster Growth and Greater Value Creation 1. ATTRACTIVE & EXPANDED PORTFOLIO Providing complete solutions across Dx and LS 2. FOCUSED INTERNAL EXECUTION Clear progress across four strategic priorities 3. STRONG FINANCIAL OUTLOOK Deliv
Slide 29: Elevating Our 2023 Forecast Vs 6 Months Ago
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO REVENUE CORE ORGANIC GROWTH OPERATING MARGIN ADJ. EPS $4.0B+ 23% $6.50+ 5-7% June 2021 Today June 2021 Today June 2021 Today June 2021 Today Expect to de-lever to < 3.0x by mid-2023 Note: Figures assume $100M of COVID-19 related revenues, 18% tax rate, and
Slide 30: Elevating Our 2023 Forecast Vs 6 Months Ago
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO REVENUE CORE ORGANIC GROWTH OPERATING MARGIN ADJ. EPS $4.5B+ $4.0B+ 23% $6.50+ 5-7% June 2021 Today June 2021 Today June 2021 Today June 2021 Today Expect to de-lever to < 3.0x by mid-2023 Note: Figures assume $100M of COVID-19 related revenues, 18% tax ra
Slide 31: Elevating Our 2023 Forecast Vs 6 Months Ago
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO REVENUE CORE ORGANIC GROWTH OPERATING MARGIN ADJ. EPS $4.5B+ 7-9% $4.0B+ 23% $6.50+ 5-7% June 2021 Today June 2021 Today June 2021 Today June 2021 Today Expect to de-lever to < 3.0x by mid-2023 Note: Figures assume $100M of COVID-19 related revenues, 18% t
Slide 32: Elevating Our 2023 Forecast Vs 6 Months Ago
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO REVENUE CORE ORGANIC GROWTH OPERATING MARGIN ADJ. EPS $4.5B+ 7-9% 26%+ $4.0B+ 23% $6.50+ 5-7% June 2021 Today June 2021 Today June 2021 Today June 2021 Today Expect to de-lever to < 3.0x by mid-2023 Note: Figures assume $100M of COVID-19 related revenues,
Slide 33: Elevating Our 2023 Forecast Vs 6 Months Ago
ELEVATING OUR 2023 FORECAST VS 6 MONTHS AGO REVENUE CORE ORGANIC GROWTH OPERATING MARGIN ADJ. EPS $4.5B+ 7-9% 26%+ $7.00+ $4.0B+ 23% $6.50+ 5-7% June 2021 Today June 2021 Today June 2021 Today June 2021 Today Expect to de-lever to < 3.0x by mid-2023 Note: Figures assume $100M of COVID-19 related rev
Slide 34: The New PerkinElmer 2023+ Profile
THE NEW PERKINELMER 2023+ PROFILE … to deliver compounding growth, strong Transformed the business … margins, and cashflow, enabling EPS growth FINANCIAL TRAJECTORY Attractive & Providing complete Organic Expanded solutions across Growth HSD Portfolio Dx and LS Margin 50-75 Expansion bps / year Focu
Slide 35: Innovating for a healthier world
Innovating for a healthier world ONE MISSION Countless Opportunities 35